What is the global regulatory approval status of estradiol/drospirenone by bayer healthcare pharmaceuticals?

Question

Accepted Answer

Region / Agency	Status	Typical Clinical Use	Brand name(s)	Key approval dates
United States – FDA	Approved for hormone‑replacement therapy (HRT) and for combined oral contraception in a few restricted studies	0.5 mg estradiol + 3 mg drospirenone daily (HRT)	FemHRT (HRT) – 2003	–
European Union – EMA	Approved for use as a combined oral contraceptive (COC) in most EU member states	0.02 mg estradiol valerate + 3 mg drospirenone daily	FemC	2005 (UK), 2007 (other EU)
United Kingdom – MHRA	Approved (same formulation as EU)	Contraception	FemC	2005
Canada – Health Canada	Approved for combined oral contraception	0.02 mg estradiol valerate + 3 mg drospirenone daily	FemC	2006
Australia – TGA	Approved for combined oral contraception	Same as EU formulation	FemC	2008
New Zealand – MedSafe	Approved for combined oral contraception	Same as EU formulation	FemC	2010
Japan – PMDA	Not approved (drospirenone is not licensed in Japan; estradiol/drospirenone product has not entered the market)	–	–	–
China – NMPA	Not approved (no regulatory filing for the combination)	–	–	–
India – CDSCO	Not approved (no regulatory filing)	–	–	–
South Africa – SAHPRA	Not approved (no regulatory filing)	–	–	–

Two distinct indications – the same active ingredients are used in different dosages/formulations for hormone‑replacement therapy (HRT) in the U.S. and for combined oral contraception in the EU, Canada, Australia, and New Zealand.
Branding differences –
- FemHRT (US, HRT) – 0.5 mg estradiol + 3 mg drospirenone.
- FemC (EU/Canada/Australia/NZ, contraception) – 0.02 mg estradiol valerate + 3 mg drospirenone.
Regulatory coverage – The product is approved in most of the Western world (U.S., EU, Canada, Australia, NZ). In Asia (Japan, China, India, South Africa), the combination has not been approved and is not commercially available.
Recent updates – As of 2024, no new approvals have been announced for the estradiol/drospirenone combination outside the regions listed above.

Bayer’s estradiol/drospirenone is globally approved in the U.S. (HRT) and in EU‑style markets (contraception).
It remains unavailable in major Asian and some other emerging markets due to regulatory or market‑entry decisions.
If you’re looking for this drug in a country outside the approved list, it’s currently not available on the market.

Ask Questions, Get Industry Insights … Instantly